Pharmaceutical Continuous Manufacturing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
Market Overview:
The global pharmaceutical continuous manufacturing market size reached US$ 1.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.3 Billion by 2028, exhibiting a growth rate (CAGR) of 11.6% during 2023-2028.
Pharmaceutical continuous manufacturing refers to an end-to-end medication production approach that enhances the quality and consistency of various novel drugs and vaccines with minimal capital investments. As compared to batch processing, it operates in a continuous flow, is easier to scale, offers greater control to manufacturers and a higher level of automation, and eliminates physical intervention. Apart from this, pharmaceutical continuous manufacturing aids in minimizing the medicine formulation duration, risk of human errors, monitoring the production procedures, and improving the product quality to harmonize with the regulatory guidelines. Consequently, the technique is extensively utilized by pharmaceutical companies and contract manufacturing organizations (CMOs) to develop active pharmaceutical ingredients (API) and medicines. At present, it is available in integrated, semi-continuous, and control types.
Pharmaceutical Continuous Manufacturing Market Trends:
One of the primary factors currently driving the market is the increasing demand for effective medicine production systems for composing various effective biologics at a lower cost. This can be further attributed to the rising drug shortages and the growing prevalence of several chronic ailments across the globe. Additionally, the rising health concerns, especially during the coronavirus disease (COVID-19) pandemic outbreak, have prompted pharmaceutical companies to use continuous manufacturing techniques to compose novel vaccines, which is acting as another growth-inducing factor. In line with this, significant technological advancements, such as rapid automation in the pharmaceutical manufacturing methodology and the large-scale integration of artificial intelligence (AI) solutions, are contributing to the market growth. Other factors, such as significant improvements in the pharmaceutical sector, ongoing research and development (R&D) activities, and the escalating awareness about the availability of food and drug administration (FDA) approved medicines, are creating a positive outlook for the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on therapeutics type, formulation, application and end user.
Breakup by Therapeutics Type:
Large Molecules
Small Molecules
Breakup by Formulation:
Solid Formulation
Liquid and Semi-solid Formulation
Breakup by Application:
Final Drug Product Manufacturing
API Manufacturing
Breakup by End User:
Pharmaceutical Companies
Contract Manufacturing Organizations
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Baker Perkins, Coperion GmbH (Hillenbrand Inc.), Eli Lilly and Company, GEA Group Aktiengesellschaft, Glatt GmbH, Korsch AG, Novartis AG, Siemens, SK biotek, Thermo Fisher Scientific Inc. and Viatris Inc.
Key Questions Answered in This Report
1. How big is the global pharmaceutical continuous manufacturing market?
2. What is the expected growth rate of the global pharmaceutical continuous manufacturing market during 2023-2028?
3. What are the key factors driving the global pharmaceutical continuous manufacturing market?
4. What has been the impact of COVID-19 on the global pharmaceutical continuous manufacturing market?
5. What is the breakup of the global pharmaceutical continuous manufacturing market based on the therapeutics type?
6. What is the breakup of the global pharmaceutical continuous manufacturing market based on formulation?
7. What is the breakup of the global pharmaceutical continuous manufacturing market based on the application?
8. What is the breakup of the global pharmaceutical continuous manufacturing market based on the end user?
9. What are the key regions in the global pharmaceutical continuous manufacturing market?
10. Who are the key players/companies in the global pharmaceutical continuous manufacturing market?
- 1 Preface
- 2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
- 5 Global Pharmaceutical Continuous Manufacturing Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
- 6 Market Breakup by Therapeutics Type
- 6.1 Large Molecules
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Small Molecules
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 7 Market Breakup by Formulation
- 7.1 Solid Formulation
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Liquid and Semi-solid Formulation
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 8 Market Breakup by Application
- 8.1 Final Drug Product Manufacturing
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 API Manufacturing
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 9 Market Breakup by End User
- 9.1 Pharmaceutical Companies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Contract Manufacturing Organizations
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
- 11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
- 12 Value Chain Analysis
- 13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
- 14 Price Analysis
- 15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Baker Perkins
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.2 Coperion GmbH (Hillenbrand Inc.)
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.3 Eli Lilly and Company
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 GEA Group Aktiengesellschaft
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.5 Glatt GmbH
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.6 Korsch AG
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.7 Novartis AG
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 Siemens
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 SK biotek
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.10 Thermo Fisher Scientific Inc.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Viatris Inc.
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook